Organ‑Protection‑First Prescribing in Diabetes Management

Paradigm Shift Overview

• The American Diabetes Association (ADA) 2020 guideline recommends initiating GLP‑1 receptor agonists (GLP‑1 RA) or SGLT2 inhibitors (SGLT2i) primarily based on the presence of cardiovascular disease (CVD), heart failure (HF), or chronic kidney disease (CKD), irrespective of a patient’s baseline HbA1c or glycemic target. Strong (Class I, Level A) evidence supports this organ‑protection‑first approach. 1

Cardiovascular Disease Management

• In adults with established atherosclerotic cardiovascular disease (e.g., prior myocardial infarction, stroke, unstable angina, or revascularization), GLP‑1 RA therapy provides the most robust reduction in major adverse cardiovascular events (MACE) and cardiovascular mortality, with relative risk reductions ranging from 12 % to 26 %. Strong (Class I, Level A) evidence underpins this recommendation. 1
• The selection of GLP‑1 RA (semaglutide, liraglutide, or dulaglutide) for ASCVD patients should be made independently of baseline HbA1c or individualized glycemic targets, emphasizing organ protection over glucose lowering. Strong (Class I, Level A) evidence. 1

Use in Patients Without Established CVD (High‑Risk Indicators)

• GLP‑1 RA may be initiated in patients without documented ASCVD who exhibit any of the following high‑risk features:

Heart Failure Management

• For patients with heart failure—particularly those with reduced ejection fraction (HFrEF, EF < 45 %)—the ADA guideline designates SGLT2 inhibitors as the preferred glucose‑lowering agents to lower the risk of HF hospitalization, MACE, and cardiovascular death, regardless of glycemic control. Strong (Class I, Level A) evidence. 1

Chronic Kidney Disease Management

• In individuals with CKD (eGFR 30–60 mL/min/1.73 m² or albuminuria > 30 mg/g, especially > 300 mg/g), SGLT2 inhibitors are recommended to slow CKD progression, reduce HF hospitalizations, and decrease MACE and cardiovascular mortality. Initiation is advised when eGFR ≥ 20 mL/min/1.73 m² and therapy can be continued until dialysis or transplantation. Strong (Class I, Level A) evidence. 1
• GLP‑1 RA retain glucose‑lowering efficacy down to eGFR ≈ 15 mL/min/1.73 m² and can attenuate albuminuria progression; when eGFR < 30 mL/min/1.73 m², GLP‑1 RA are preferred over SGLT2i because of a lower risk of hypoglycemia. Moderate (Class IIa, Level B) evidence. 1

Hypoglycemia Definition and Management

• The ADA 2018 update standardizes clinically significant hypoglycemia as Level 2 hypoglycemia (blood glucose < 54 mg/dL [3.0 mmol/L]). Strong (Class I, Level A) evidence. 2
• Patients experiencing Level 2 hypoglycemia should have their glycemic targets temporarily relaxed to avoid further episodes and to help reverse hypoglycemia unawareness over several weeks. Strong (Class I, Level A) evidence. 2

Practical Implementation Recommendations

• Clinicians should avoid delaying initiation of GLP‑1 RA or SGLT2i in patients with established CVD, HF, or CKD while awaiting an elevated HbA1c; organ‑protective therapy takes precedence over glycemic thresholds. Strong (Class I, Level A) evidence. 1

Initiating SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetes Mellitus

Patient-Specific Recommendations

• The American Diabetes Association recommends SGLT2 inhibitors as first-line therapy for patients with established atherosclerotic cardiovascular disease to reduce major adverse cardiovascular events, hospitalization for heart failure, and cardiovascular death 3, 4
• The American College of Cardiology suggests SGLT2 inhibitors for patients with heart failure, particularly those with reduced ejection fraction, regardless of baseline blood sugar control 3, 4
• The National Kidney Foundation recommends SGLT2 inhibitors for patients with chronic kidney disease, especially those with an estimated glomerular filtration rate between 30-60 mL/min/1.73m² or urinary albumin-to-creatinine ratio greater than 30 mg/g 3, 4, 5
• The American College of Cardiology advises initiating SGLT2 inhibitors when the estimated glomerular filtration rate is ≥20 mL/min/1.73m² and continuing as tolerated until dialysis or transplantation 5
• The American Diabetes Association recommends reducing the dose of sulfonylurea by 50% or basal insulin by 20% when starting SGLT2 inhibitor therapy if blood sugar is well-controlled at baseline 6, 7
• The American College of Cardiology suggests monitoring for genital mycotic infections and providing education on genital hygiene when using SGLT2 inhibitors 6, 7
• The National Kidney Foundation recommends assessing for volume depletion and considering reducing diuretic doses if necessary when starting SGLT2 inhibitors 6, 7
• The American College of Cardiology advises using SGLT2 inhibitors with caution in patients with foot ulcers or at high risk for amputation, particularly with canagliflozin 3, 6

GLP-1 Receptor Agonists

• The American Diabetes Association recommends GLP-1 receptor agonists for patients with established atherosclerotic cardiovascular disease to reduce major adverse cardiovascular events 3, 4, 8
• The American College of Cardiology suggests GLP-1 receptor agonists for patients without established cardiovascular disease but with high-risk indicators, such as age ≥55 years with coronary, carotid, or lower extremity artery stenosis >50% 3, 4, 8
• The American Heart Association recommends GLP-1 receptor agonists for patients with obesity where weight loss is a priority 6, 8
• The National Kidney Foundation advises using GLP-1 receptor agonists when SGLT2 inhibitors are contraindicated or not tolerated 5, 8
• The American College of Cardiology recommends starting GLP-1 receptor agonists at the lowest dose and titrating slowly to mitigate nausea 6, 7
• The American Diabetes Association suggests discontinuing DPP-4 inhibitors before starting GLP-1 receptor agonists 6, 7
• The American College of Cardiology advises reducing insulin dose by approximately 20% when initiating GLP-1 receptor agonist therapy if blood sugar is well-controlled 7
• The American Heart Association recommends using GLP-1 receptor agonists with caution in patients with a history of pancreatitis, gastroparesis, or medullary thyroid cancer 6

Combined Use Considerations

• The American College of Cardiology suggests considering combination therapy with both SGLT2 inhibitors and GLP-1 receptor agonists in high-risk patients with multiple comorbidities 5
• The American Diabetes Association recommends prioritizing GLP-1 receptor agonists for patients with atherosclerotic disease and SGLT2 inhibitors for patients with heart failure or chronic kidney disease 3, 4, 5